Focused Wealth Management’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Focused Wealth Management’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,250	Closed	-$1K	–	770
2018 Q1	$1K	Hold	9,250	–	–	﹤0.01%	682
2017 Q4	$1K	Buy	+9,250	New	+$1K	﹤0.01%	667
2017 Q3	–	Sell	-12,205	Closed	–	–	773
2017 Q2	$0	Hold	12,205	–	–	﹤0.01%	770
2017 Q1	$1K	Buy	12,205 +9,250	+313%	+$758	﹤0.01%	676
2016 Q4	$0	Hold	2,955	–	–	﹤0.01%	765
2016 Q3	$0	Hold	2,955	–	–	﹤0.01%	729
2016 Q2	$1K	Hold	2,955	–	–	﹤0.01%	653
2016 Q1	$1K	Hold	2,955	–	–	﹤0.01%	636
2015 Q4	$1K	Hold	2,955	–	–	﹤0.01%	663
2015 Q3	$2K	Hold	2,955	–	–	﹤0.01%	614
2015 Q2	$2K	Buy	2,955 +750	+34%	+$612	﹤0.01%	598
2015 Q1	$2K	Buy	2,205 +500	+29%	+$412	﹤0.01%	617
2014 Q4	$1K	Buy	+1,705	New	+$1.56K	﹤0.01%	644

Other funds holding PVCT

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

BRR OpCo Columbus, Ohio $814M AUM 9.75% 1-Year Est. Return

QCIG

Quad-Cities Investment Group Davenport, Iowa $278M AUM 22.38% 1-Year Est. Return

Focused Wealth Management's PVCT Position: Q2 2018 in Review

Focused Wealth Management sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q2 2018, closing a stake of 9,250 shares — an estimated $1K sold.

Focused Wealth Management first reported a position in PVCT in Q4 2014 and held it in 13 quarters. The position peaked at $2K in Q3 2015. 3 funds tracked by Wall St. Rank hold PVCT as of Q2 2018.

Focused Wealth Management reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q2 2018 after selling out during the quarter.
Focused Wealth Management sold 9,250 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q2 2018, an estimated $1K.
Focused Wealth Management first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 13 quarters.
Focused Wealth Management's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $2K in Q3 2015.
3 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q2 2018.

Based on Focused Wealth Management's 13F filing for Q2 2018, filed 15 Aug 2018.